Advances in von Willebrand disease (VWD): A view from the clinic

ISTH, 30th Annual Congress, July 9–13, 2022 

Watch the full video recording of the CSL Behring VWD Product Theatre held on July 11, 2022.

The meeting was chaired by Augusto Federici (Italy) and was followed by three presentations, given by himself, Susan Halimeh (Germany) and Carolyn Millar (UK). The presentations focused on specific patient cases, detailing various experiences in the treatment of VWD. The session finished with an interactive question and answer session with the faculty and audience, which was moderated by Susan Halimeh.

Please note that this product theatre contains information on specific products and indications. The Summary of Product Characteristics (SmPC) and/or local prescribing information provided may vary depending on local approval in each country. Haemate^® P is not licensed for use in the UK. Voncento^® is licensed for use in the UK. Best efforts were undertaken by CSL Behring and congress sponsors to ensure compliance with EFPIA Code of Practice in line with the Joint Guidelines (IFPMA, EFPIA and PhRMA). However, you should review your local prescribing information and/or SmPC and consult directly with the local affiliate of CSL Behring to address any questions.